(Q43557342)

24 November 2017

Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells (English)

1 reference

24 November 2017

1 reference

Zhao R

1

1 reference

24 November 2017

Gao F

series ordinal

2

1 reference

24 November 2017

Goldman ID

series ordinal

3

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

24 November 2017

Biochemical Pharmacology

1 reference

24 November 2017

61

1 reference

24 November 2017

7

1 reference

24 November 2017

857-865

1 reference

Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

The effect of folic acid fortification on plasma folate and total homocysteine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Biochemical pharmacology of the lipophilic antifolate, trimetrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Polyglutamation of methotrexate. Is methotrexate a prodrug?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Mammalian folylpoly-gamma-glutamate synthetase. 4. In vitro and in vivo metabolism of folates and analogues and regulation of folate homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Studies with a mathematical model of folate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900532-9

10.1016/S0006-2952(01)00532-9

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference